Daxor Corporation (NASDAQ: DXR) Stock Competitors & Peer Comparison
See DXR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DXR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $9.75 | -4.44% | 57.2M | 25.63 | $0.38 | N/A |
| ISRG | $399.91 | +2.45% | 138.2B | 40.66 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.05% |
| BDX | $186.40 | +1.63% | 50.2B | 14.01 | $13.00 | +2.05% |
| MDLN | $33.97 | -2.61% | 28.9B | 25.00 | $1.36 | N/A |
| WST | $354.70 | +2.33% | 24.4B | 43.50 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $88.08 | +1.45% | 15.1B | 12.31 | $7.10 | N/A |
| COO | $77.11 | +2.67% | 14.8B | 16.61 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.05% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
DXR vs ISRG Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ISRG has a market cap of 138.2B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ISRG trades at $399.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ISRG's P/E ratio is 40.66. In terms of profitability, DXR's ROE is +0.22%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
DXR vs BDXA Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BDXA's P/E ratio is 45.70. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
DXR vs BDX Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BDX has a market cap of 50.2B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BDX trades at $186.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BDX's P/E ratio is 14.01. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
DXR vs MDLN Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, MDLN has a market cap of 28.9B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while MDLN trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas MDLN's P/E ratio is 25.00. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
DXR vs WST Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, WST has a market cap of 24.4B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while WST trades at $354.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas WST's P/E ratio is 43.50. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.19%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
DXR vs HOLX Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
DXR vs SOLV Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, SOLV has a market cap of 15.1B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while SOLV trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas SOLV's P/E ratio is 12.31. In terms of profitability, DXR's ROE is +0.22%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for DXR.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
DXR vs COO Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, COO has a market cap of 14.8B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while COO trades at $77.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas COO's P/E ratio is 16.61. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
DXR vs BDXB Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
DXR vs BAX Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BAX has a market cap of 13.4B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BAX trades at $26.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BAX's P/E ratio is 12.46. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.17%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
Repligen Corporation (NASDAQ: RGEN)
DXR vs RGEN Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, RGEN has a market cap of 9.4B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while RGEN trades at $175.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas RGEN's P/E ratio is 92.31. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
DXR vs AVTR Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, AVTR has a market cap of 9B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while AVTR trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas AVTR's P/E ratio is 15.72. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
DXR vs ATR Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ATR trades at $132.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ATR's P/E ratio is 23.03. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
DXR vs BLCO Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BLCO trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BLCO's P/E ratio is 26.12. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
DXR vs TFX Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while TFX trades at $136.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas TFX's P/E ratio is 15.08. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.32%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
DXR vs STVN Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while STVN trades at $21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas STVN's P/E ratio is 32.13. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
DXR vs MMSI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while MMSI trades at $91.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas MMSI's P/E ratio is 22.83. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
DXR vs ICUI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ICUI trades at $187.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ICUI's P/E ratio is 22.94. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, DXR is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
DXR vs NVST Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NVST trades at $28.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NVST's P/E ratio is 18.93. In terms of profitability, DXR's ROE is +0.22%, compared to NVST's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
DXR vs PLSE Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, PLSE has a market cap of 3.2B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while PLSE trades at $47.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas PLSE's P/E ratio is -38.98. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, DXR is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
DXR vs ATRC Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ATRC has a market cap of 2.3B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ATRC trades at $47.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ATRC's P/E ratio is 1421.12. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
DXR vs XRAY Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while XRAY trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas XRAY's P/E ratio is 7.77. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, DXR is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
DXR vs LMAT Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while LMAT trades at $83.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas LMAT's P/E ratio is 29.97. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
DXR vs BLFS Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while BLFS trades at $36.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas BLFS's P/E ratio is -167.73. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, DXR is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
DXR vs KMTS Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while KMTS trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas KMTS's P/E ratio is -11.83. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, DXR is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
Azenta, Inc. (NASDAQ: AZTA)
DXR vs AZTA Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while AZTA trades at $35.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas AZTA's P/E ratio is 79.95. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
STAAR Surgical Company (NASDAQ: STAA)
DXR vs STAA Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while STAA trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas STAA's P/E ratio is 43.23. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of +0.01%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
DXR vs QDEL Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, QDEL has a market cap of 915.8M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while QDEL trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas QDEL's P/E ratio is 10.02. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, DXR is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
DXR vs ATRI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
DXR vs ANGO Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ANGO has a market cap of 653.9M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ANGO trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ANGO's P/E ratio is -40.56. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, DXR is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
DXR vs NNNN Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NNNN has a market cap of 366.5M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NNNN trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NNNN's P/E ratio is 120.66. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
DXR vs SMTI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, SMTI has a market cap of 314.1M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while SMTI trades at $34.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas SMTI's P/E ratio is -569.50. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, DXR is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
DXR vs OSUR Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, OSUR has a market cap of 258.2M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while OSUR trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas OSUR's P/E ratio is -6.82. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
DXR vs INFU Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, INFU has a market cap of 246.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while INFU trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas INFU's P/E ratio is 29.78. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.15%. Regarding short-term risk, DXR is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
DXR vs UTMD Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, UTMD has a market cap of 229.3M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while UTMD trades at $72.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas UTMD's P/E ratio is 21.30. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
DXR vs PDEX Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while PDEX trades at $68.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas PDEX's P/E ratio is 23.55. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
DXR vs KRMD Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, KRMD has a market cap of 153M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while KRMD trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas KRMD's P/E ratio is -83.25. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, DXR is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
DXR vs MBOT Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, MBOT has a market cap of 67M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while MBOT trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas MBOT's P/E ratio is -5.65. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, DXR is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
DXR vs AKYA Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
DXR vs STSS Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.54%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
DXR vs OMIC Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
DXR vs IGAP Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
DXR vs NEPH Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NEPH has a market cap of 49.8M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NEPH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NEPH's P/E ratio is 76.50. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
DXR vs POCI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, POCI has a market cap of 47.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while POCI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas POCI's P/E ratio is -6.02. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
DXR vs MLSS Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, MLSS has a market cap of 43.3M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while MLSS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas MLSS's P/E ratio is -8.16. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
DXR vs HBIO Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, HBIO has a market cap of 31.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while HBIO trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas HBIO's P/E ratio is -19.36. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, DXR is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
DXR vs SDC Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
DXR vs IVC Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
DXR vs ZJYL Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ZJYL has a market cap of 24.1M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ZJYL trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ZJYL's P/E ratio is 19.25. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
Retractable Technologies, Inc. (AMEX: RVP)
DXR vs RVP Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, RVP has a market cap of 21.7M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas RVP's P/E ratio is -2.20. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.05%. Regarding short-term risk, DXR is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
DXR vs RGNT Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, RGNT has a market cap of 14M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while RGNT trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas RGNT's P/E ratio is -0.08. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
DXR vs FEMY Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, FEMY has a market cap of 6.6M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while FEMY trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas FEMY's P/E ratio is -6.08. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
DXR vs NSTG Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
Lucyd, Inc (NASDAQ: LUCY)
DXR vs LUCY Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, LUCY has a market cap of 4.5M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while LUCY trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas LUCY's P/E ratio is -0.43. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, DXR is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
DXR vs POAI Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of -21.19%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
DXR vs NXGL Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NXGL trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NXGL's P/E ratio is -0.55. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, DXR is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
DXR vs GCTK Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, GCTK has a market cap of 2.6M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while GCTK trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas GCTK's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -21.36%. Regarding short-term risk, DXR is more volatile compared to GCTK. This indicates higher risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
DXR vs MHUA Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
DXR vs GMVD Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
DXR vs GMVDW Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
DXR vs NXGLW Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, NXGLW has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas NXGLW's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
Avinger, Inc. (NASDAQ: AVGR)
DXR vs AVGR Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
DXR vs LUCYW Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
DXR vs APR Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
DXR vs ATRS Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
DXR vs HRC Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
DXR vs IIN Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
DXR vs ALOG Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas ALOG's P/E ratio is 40.93. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
DXR vs IVTY Comparison August 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 57.2M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $9.75 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 25.63, whereas IVTY's P/E ratio is -3.80. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here